Finance

Lists
GYRE:NASDAQ
Gyre Therapeutics Inc
US$ ४.३१
+०.२३%
(+०.०१००) 1D
US$ ४.३०
-०.२३% (-०.०१००)
After hours
Closed: नोभेम्बर १३, १६:००:०१ GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GYRE...
Open
US$ ४.६६
High
US$ ४.७५
Low
US$ ४.१५
Mkt. cap
४७.१७ करोड
Avg. vol.
१.७१ लाख
Volume
२.८१ लाख
52-wk high
US$ ९.१४
52-wk low
US$ ३.९७
EPS
-US$ ०.२०
Beta
२.४३
Shares outstanding
१०.६० करोड
No. of employees
६२५
Open
US$ ४.६६
High
US$ ४.७५
Low
US$ ४.१५
Mkt. cap
४७.१७ करोड
Avg. vol.
१.७१ लाख
Volume
२.८१ लाख
52-wk high
US$ ९.१४
52-wk low
US$ ३.९७
EPS
-US$ ०.२०
Beta
२.४३
Shares outstanding
१०.६० करोड
No. of employees
६२५
News stories
From web sources and news partners
qz.com
qz.com
·
९ घण्टा पहिले
How much of the S&P 500 is Nvidia? Concentration explained
marketscreener.com
marketscreener.com
·
१० घण्टा पहिले
S&P 500 Posts Weekly Gain as Energy Sector Leads Broad Climb
Investing.com
Investing.com
·
१० घण्टा पहिले
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.10%
About Gyre Therapeutics Inc
CEO-
Employees६२५
Founded१९९७
Headquartersविन्सटन-सलेम, नर्थ क्यारोलाइना, संयुक्त राज्य अमेरिका
SectorHealth Care
Industry-
Websitegyretx.com
Analyst ratings
Based on 1 analyst giving stock ratings to GYRE in the past 3 months
Buy
Buy
1
Hold
0
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for GYRE in the last 3 months
Highest
Current US$ ४.३१
US$ १८.०० (+३१७.६३%)
Average
US$ १८.०० (+३१७.६३%)
Lowest
US$ १८.०० (+३१७.६३%)
Analyst
Recommendation
Action
Price target
Projected
Date
Matthew Keller
H.C. Wainwright
Buy
Reiterated
US$ १८.००
+३१७.६%
11/06/2026
Robert LeBoyer
Noble Financial
Buy
Reiterated
US$ २०.००
+३६४%
08/10/2026
Roger Song
Jefferies
Buy
Initiated
US$ १६.००
+२७१.२%
10/10/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
२०२६ सेप्टेम्बर
Revenue
३.७२ करोड
२.४४ करोड
२.९१ करोड
३.२९ करोड
Cost of goods sold
१७.४३ लाख
१२.२७ लाख
२२.०९ लाख
१९.४७ लाख
Cost of revenue
१७.४३ लाख
१२.२७ लाख
२२.०९ लाख
१९.४७ लाख
Research and development expenses
४८.१५ लाख
१.१५ करोड
१.९१ करोड
८५.०८ लाख
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
३.०५ करोड
२.४३ करोड
२.१६ करोड
२.३९ करोड
Operating expense
३.५३ करोड
३.५८ करोड
४.०८ करोड
३.२५ करोड
Total operating expenses
३.७१ करोड
३.७० करोड
४.३० करोड
३.४४ करोड
Operating income
१.२० लाख
-१.२६ करोड
-१.३९ करोड
-१४.७० लाख
Other non operating income
-२३.११ लाख
२.४४ लाख
-११.८९ लाख
-९.१३ लाख
EBT including unusual items
-६६.०० हजार
-१.८० करोड
-१.८३ करोड
-१७.४५ लाख
EBT excluding unusual items
-८.६४ लाख
-१.१६ करोड
-१.३९ करोड
-१६.९५ लाख
Income tax expense
१३.०० लाख
५.४९ लाख
-१.६४ लाख
७.३३ लाख
Effective tax rate
-१,९६९.७०%
-३.०४%
०.८९%
-४२.०१%
Other operating expenses
-
-
-
-
Net income
-१७.२३ लाख
-१.०३ करोड
-१.४५ करोड
-४०.५३ लाख
Net profit margin
-४.६३%
-४२.१६%
-४९.८५%
-१२.३१%
Earnings per share
०.०५
-
-
-
Interest and investment income
१३.४७ लाख
७.४३ लाख
११.४० लाख
६.८८ लाख
Interest expense
-
-
-
-
Net interest expenses
१३.४७ लाख
७.४३ लाख
११.४० लाख
६.८८ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
८.१५ लाख
-१.१९ करोड
-१.२४ करोड
-१०.०३ लाख
Gain or loss from assets sale
२.०० हजार
१६.०० हजार
२.०० हजार
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google एपहरू